
Please try another search
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Paula H. J. Cholmondeley | 77 | 2021 | Independent Director |
Reinaldo M. Diaz | 70 | 2022 | Independent Director |
Steven M. Altschuler Buser | 71 | 2021 | Independent Chairman of the Board |
Mette Kirstine Agger | 60 | 2020 | Independent Director |
Marianna Fontana | - | 2022 | Member of Scientific Advisory Board |
Iacopo Olivotto | - | 2022 | Member of Scientific Advisory Board |
Kiran Musunuru | - | 2022 | Member of Scientific Advisory Board |
R. Nolan Townsend | 43 | 2020 | CEO & Director |
Victoria Parikh | - | 2022 | Member of Scientific Advisory Board |
Eugene W. Yeo | 47 | 2022 | Member of Scientific Advisory Board |
Jeffery D. Molkentin | - | 2022 | Member of Scientific Advisory Board |
Brenda G. Cooperstone | 59 | 2023 | Independent Director |
Timothy Van Hauwermeiren | 52 | 2024 | Independent Non-Executive Director |
Tolga Tanguler | 52 | 2024 | Independent Director |
Ronald G. Crystal | - | 2022 | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review